Technische Universität München

The Entrepreneurial University

The combined use of clenbuterol and AAS seems to increase the risk of renal failure especially in pre-existing kidney diseases. In such cases, the renal biopsy may reveal nephrosclerosis with pronounced obstructive lesions of preglomerular vessels, hypertension-like vascular damage, global glomerulosclerosis and diffuse chronic tubulo-interstitial damage. Beta-adrenergic substances may lead to acceleration of a hypertensive renal damage process. High to toxic doses of clenbuterol are found to cause a remarkable beta-adrenergic receptor down-regulation in rats. An additional adverse effect of clenbuterol may be interstitial nephritis and hypertensive nephrosclerosis.